Bain Capital and Cinven are holding talks for a 10 billion euros sale of the German pharmaceutical company after having called off the IPO for market volatility
Stada Arzneimittel, a German pharmaceutical company that belongs to Bain Capital and Cinven, attracted the interest of CapVest Partners. The deal could be worth 10 billion euros, or 11X – 13X the firm’s ebitda that in 2024 amounted to 886 million (adjusted) (+11% from 2023), Bloomberg said.
Peter Goldschmidt is the ceo of Stada which generated a 2024 turnover of above 4.1 billion (press release). In 1Q25, sales amounted to 1.081 billion (+4.1%) and the ebitda to 245 million (+5%) (press release).
The Financial Times previously reported that the funds were mulling for the launch of an ipo and fetch 1.5 billion (see here a previous post by BeBeez) but suspended such plans for markets volatility. Before such a listing attempt, Bain Capital and Cinven also held talks for selling Stada to Clayton Dubilier & Rice and GTCR (Bloomberg).
Stada one of the main European producer of OTC and generic drugs was born was born in in 1895. Bain and Cinven delisted the company from Franckfurt exchange in 2017 on the ground of an enterprise value of 5.3 billion (press release).
